205 related articles for article (PubMed ID: 22746187)
21. Advances in nanotechnology-based carrier systems for targeted delivery of bioactive drug molecules with special emphasis on immunotherapy in drug resistant tuberculosis - a critical review.
Singh J; Garg T; Rath G; Goyal AK
Drug Deliv; 2016 Jun; 23(5):1676-98. PubMed ID: 26289212
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of Nanocarrier-Based Dry Powder Formulations for Inhalation with Special Reference to Anti-Tuberculosis Drugs.
Patil TS; Deshpande A; Shende PK; Deshpande S; Gaud R
Crit Rev Ther Drug Carrier Syst; 2019; 36(3):239-276. PubMed ID: 31679248
[TBL] [Abstract][Full Text] [Related]
23. [Recent progress in mycobacteriology].
Okada M; Kobayashi K
Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
[TBL] [Abstract][Full Text] [Related]
24. Nanomedicines as Drug Delivery Carriers of Anti-Tubercular Drugs: From Pathogenesis to Infection Control.
Hussain A; Singh S; Das SS; Anjireddy K; Karpagam S; Shakeel F
Curr Drug Deliv; 2019; 16(5):400-429. PubMed ID: 30714523
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapeutic potential of alginate-chitosan microspheres as anti-tubercular drug carriers.
Pandey R; Khuller GK
J Antimicrob Chemother; 2004 Apr; 53(4):635-40. PubMed ID: 14998985
[TBL] [Abstract][Full Text] [Related]
26. Mycobactericidal activity of some micro-encapsulated synthetic Host Defense Peptides (HDP) by expediting the permeation of antibiotic: A new paradigm of drug delivery for tuberculosis.
Sharma A; Vaghasiya K; Ray E; Gupta P; Kumar Singh A; Datta Gupta U; Kumar Verma R
Int J Pharm; 2019 Mar; 558():231-241. PubMed ID: 30630076
[TBL] [Abstract][Full Text] [Related]
27. Development and characterization of spray-dried porous nanoaggregates for pulmonary delivery of anti-tubercular drugs.
Kaur R; Garg T; Malik B; Gupta UD; Gupta P; Rath G; Goyal AK
Drug Deliv; 2016; 23(3):882-7. PubMed ID: 24870203
[TBL] [Abstract][Full Text] [Related]
28. Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis.
Machelart A; Salzano G; Li X; Demars A; Debrie AS; Menendez-Miranda M; Pancani E; Jouny S; Hoffmann E; Deboosere N; Belhaouane I; Rouanet C; Simar S; Talahari S; Giannini V; Villemagne B; Flipo M; Brosch R; Nesslany F; Deprez B; Muraille E; Locht C; Baulard AR; Willand N; Majlessi L; Gref R; Brodin P
ACS Nano; 2019 Apr; 13(4):3992-4007. PubMed ID: 30822386
[TBL] [Abstract][Full Text] [Related]
29. Respirable nanocarriers as a promising strategy for antitubercular drug delivery.
Mehanna MM; Mohyeldin SM; Elgindy NA
J Control Release; 2014 Aug; 187():183-97. PubMed ID: 24878180
[TBL] [Abstract][Full Text] [Related]
30. Advanced drug delivery and therapeutic strategies for tuberculosis treatment.
Nair A; Greeny A; Nandan A; Sah RK; Jose A; Dyawanapelly S; Junnuthula V; K V A; Sadanandan P
J Nanobiotechnology; 2023 Nov; 21(1):414. PubMed ID: 37946240
[TBL] [Abstract][Full Text] [Related]
31. Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis.
Pandey R; Zahoor A; Sharma S; Khuller GK
Tuberculosis (Edinb); 2003; 83(6):373-8. PubMed ID: 14623168
[TBL] [Abstract][Full Text] [Related]
32. Natural carriers for application in tuberculosis treatment.
Costa H; Grenha A
J Microencapsul; 2013; 30(3):295-306. PubMed ID: 22991962
[TBL] [Abstract][Full Text] [Related]
33. Spray Dried Aerosol Particles of Pyrazinoic Acid Salts for Tuberculosis Therapy. [Corrected].
Durham PG; Zhang Y; German N; Mortensen N; Dhillon J; Mitchison DA; Fourie PB; Hickey AJ
Mol Pharm; 2015 Aug; 12(8):2574-81. PubMed ID: 26098136
[TBL] [Abstract][Full Text] [Related]
34. Managing TB in the 21st century: existing and novel drug therapies.
Guy ES; Mallampalli A
Ther Adv Respir Dis; 2008 Dec; 2(6):401-8. PubMed ID: 19124385
[TBL] [Abstract][Full Text] [Related]
35. Potential role of adjuvant drugs on efficacy of first line oral antitubercular therapy: Drug repurposing.
Mishra R; Krishan S; Siddiqui AN; Kapur P; Khayyam KU; Sharma M
Tuberculosis (Edinb); 2020 Jan; 120():101902. PubMed ID: 32090863
[TBL] [Abstract][Full Text] [Related]
36. Novel chemotherapy for tuberculosis: chemotherapeutic potential of econazole- and moxifloxacin-loaded PLG nanoparticles.
Ahmad Z; Pandey R; Sharma S; Khuller GK
Int J Antimicrob Agents; 2008 Feb; 31(2):142-6. PubMed ID: 18155883
[TBL] [Abstract][Full Text] [Related]
37. Antimicrobial peptides as novel anti-tuberculosis therapeutics.
Silva JP; Appelberg R; Gama FM
Biotechnol Adv; 2016; 34(5):924-940. PubMed ID: 27235189
[TBL] [Abstract][Full Text] [Related]
38. Chemotherapeutic efficacy of poly (DL-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis.
Sharma A; Pandey R; Sharma S; Khuller GK
Int J Antimicrob Agents; 2004 Dec; 24(6):599-604. PubMed ID: 15555884
[TBL] [Abstract][Full Text] [Related]
39. Inhaled dry powder formulations for treating tuberculosis.
Das S; Tucker I; Stewart P
Curr Drug Deliv; 2015; 12(1):26-39. PubMed ID: 25030114
[TBL] [Abstract][Full Text] [Related]
40. Inhaled Solid Lipid Microparticles to target alveolar macrophages for tuberculosis.
Maretti E; Rossi T; Bondi M; Croce MA; Hanuskova M; Leo E; Sacchetti F; Iannuccelli V
Int J Pharm; 2014 Feb; 462(1-2):74-82. PubMed ID: 24374224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
